
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp is positioned for a positive financial outlook due to expected revenue acceleration in 2026 and beyond, supported by strong international momentum despite temporary challenges in China. The company is focused on disciplined investment, reaffirming a gross margin guidance of 74% for 2025 while tightening operating expense expectations to $128 million–$130 million. Additionally, the successful execution of their AeriSeal convert trial and the integration of AI-driven tools like LungTraX Detect will be crucial for expanding global access and enhancing patient identification, ultimately driving sustained adoption of their products.
Bears say
Pulmonx Corp faces a challenging financial landscape due to its reliance on a limited product range that may hinder revenue diversification, primarily generated through sales of its Zephyr Endobronchial Valve and related systems. Additionally, the company has experienced sluggish growth in key markets, particularly in the U.S., where competitive pressures and product adoption rates pose significant risks to its financial stability. Furthermore, ongoing operational costs and potential regulatory hurdles could impact profitability and overall market performance, contributing to a negative outlook on the company’s stock.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares